Clinical Trial Update: A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating ambrisentan and tadalafil in pulmonary arterial hypertension associated with systemic sclerosis; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Systemic Sclerosis

Drugs mentioned

• Ambrisentan (Ambrisentan)
• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Johns Hopkins University | Conditions: Pulmonary Arterial Hypertension, Systemic Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2017-09-12